Quantcast

Latest chronic migraine Stories

2014-01-08 08:28:02

SAN MATEO, Calif., Jan. 8, 2014 /PRNewswire/ -- Labrys Biologics Inc., a biotechnology company focused on treatments for migraine, today announced that patients are now being enrolled in two separate Phase 2b clinical studies of LBR-101 (formerly RN-307) as a subcutaneous once-monthly treatment for the prevention of frequent migraines. The first study is enrolling subjects with chronic migraine, who experience at least 15 headache days per month. The second study is enrolling subjects...


Word of the Day
malpais
  • The ragged surface of a lava-flow.
'Malpais' translates from Spanish as 'bad land.'